Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

by Gretchen E Glaser, Gerardo Colon-Otero, Valentina Zanfagnin, Xiaonan Hou, Nathan R Foster, Erik J Asmus, Andrea Wahner Hendrickson, Aminah Jatoi, Matthew S Block, Carrie L Langstraat, Tri A Dinh, Matthew W Robertson, John K Camoriano, Kristina A Butler, John A Copland, S John Weroha
Published 2020-10-01